Toward a more precise prognostic stratification in acute decompensation of cirrhosis: The Padua model 2.0.
acute decompensation
acute on chronic liver failure
liver cirrhosis
presepsin
Journal
United European gastroenterology journal
ISSN: 2050-6414
Titre abrégé: United European Gastroenterol J
Pays: England
ID NLM: 101606807
Informations de publication
Date de publication:
11 2023
11 2023
Historique:
received:
24
04
2023
accepted:
21
07
2023
medline:
13
11
2023
pubmed:
4
10
2023
entrez:
4
10
2023
Statut:
ppublish
Résumé
The clinical course of acutely decompensated cirrhosis (AD) is heterogeneous. Presepsin (PSP) is a plasmatic biomarker that reflects Toll-like receptor activity and systemic inflammation. We conducted a prospective study to: (1) measure PSP in AD and (2) assess whether PSP in AD can predict the development of acute-on-chronic liver failure (ACLF). Patients with AD were prospectively recruited at admission and underwent determination of PSP. In study part 1, we compared PSP in AD versus controls (stable decompensated and compensated cirrhosis). In study part 2, we prospectively followed patients with AD for 1 year and evaluated predictors of ACLF. One hundred and seventy three patients with AD were included (median MELD: 18; CLIF-C AD score: 54). Compared with controls, patients with AD had higher levels of PSP (674 ng/L vs. 310 ng/L vs. 157 ng/L; p < 0.001). In patients with AD, Child-Pugh C and acute kidney injury were associated with higher levels of PSP. During the follow-up, 52 patients developed ACLF (median time from recruitment: 66 days). PSP, CLIF-C AD score, and Child-Pugh stage were independently associated with ACLF. A predictive model combining these variables (Padua model 2.0) accurately identified patients at higher risk of ACLF (AUROC 0.864; 95% CI 0.780-0.947; sensitivity 82.9%, specificity 76.7%). In patients at lower risk of ACLF based on a CLIF-C AD <50, a PSP >674 ng/L could discriminate between two groups at significantly different risk of ACLF. Finally, in patients who did not develop ACLF, baseline PSP was significantly higher in those who progressed toward unstable versus stable decompensated cirrhosis. The Padua model 2.0 can be used to identify patients with AD at high risk of ACLF. If these results are validated by external cohorts, PSP could become a new biomarker to improve risk stratification in AD.
Sections du résumé
BACKGROUND
The clinical course of acutely decompensated cirrhosis (AD) is heterogeneous. Presepsin (PSP) is a plasmatic biomarker that reflects Toll-like receptor activity and systemic inflammation. We conducted a prospective study to: (1) measure PSP in AD and (2) assess whether PSP in AD can predict the development of acute-on-chronic liver failure (ACLF).
METHODS
Patients with AD were prospectively recruited at admission and underwent determination of PSP. In study part 1, we compared PSP in AD versus controls (stable decompensated and compensated cirrhosis). In study part 2, we prospectively followed patients with AD for 1 year and evaluated predictors of ACLF.
RESULTS
One hundred and seventy three patients with AD were included (median MELD: 18; CLIF-C AD score: 54). Compared with controls, patients with AD had higher levels of PSP (674 ng/L vs. 310 ng/L vs. 157 ng/L; p < 0.001). In patients with AD, Child-Pugh C and acute kidney injury were associated with higher levels of PSP. During the follow-up, 52 patients developed ACLF (median time from recruitment: 66 days). PSP, CLIF-C AD score, and Child-Pugh stage were independently associated with ACLF. A predictive model combining these variables (Padua model 2.0) accurately identified patients at higher risk of ACLF (AUROC 0.864; 95% CI 0.780-0.947; sensitivity 82.9%, specificity 76.7%). In patients at lower risk of ACLF based on a CLIF-C AD <50, a PSP >674 ng/L could discriminate between two groups at significantly different risk of ACLF. Finally, in patients who did not develop ACLF, baseline PSP was significantly higher in those who progressed toward unstable versus stable decompensated cirrhosis.
CONCLUSION
The Padua model 2.0 can be used to identify patients with AD at high risk of ACLF. If these results are validated by external cohorts, PSP could become a new biomarker to improve risk stratification in AD.
Identifiants
pubmed: 37792602
doi: 10.1002/ueg2.12472
pmc: PMC10637119
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
815-824Informations de copyright
© 2023 The Authors. United European Gastroenterology Journal published by Wiley Periodicals LLC on behalf of United European Gastroenterology.
Références
J Hepatol. 2022 Sep;77(3):660-669
pubmed: 35364225
JHEP Rep. 2022 Apr 20;4(7):100493
pubmed: 35647501
Dig Liver Dis. 2021 Jul;53(7):879-888
pubmed: 33431230
United European Gastroenterol J. 2023 Nov;11(9):815-824
pubmed: 37792602
J Hepatol. 2023 Feb;78(2):301-311
pubmed: 36150575
Ann Gastroenterol. 2018 Sep-Oct;31(5):604-612
pubmed: 30174398
J Hepatol. 2021 Mar;74(3):670-685
pubmed: 33301825
Gastroenterology. 2013 Jun;144(7):1426-37, 1437.e1-9
pubmed: 23474284
Hepatology. 2003 Jan;37(1):208-17
pubmed: 12500206
Biomed Pharmacother. 2019 Mar;111:649-656
pubmed: 30611989
J Hepatol. 2022 Apr;76(4):959-974
pubmed: 35120736
J Hepatol. 2014 Jun;60(6):1310-24
pubmed: 24530646
PLoS One. 2015 Jun 01;10(6):e0129159
pubmed: 26030716
J Hepatol. 2020 Oct;73(4):842-854
pubmed: 32673741
United European Gastroenterol J. 2021 May;9(4):427-437
pubmed: 34050619
J Hepatol. 2022 Jan;76(1):202-207
pubmed: 34157322
J Hepatol. 2023 May;78(5):1037-1047
pubmed: 36708812
J Clin Med. 2021 Oct 05;10(19):
pubmed: 34640608
Clin Chim Acta. 2015 Oct 23;450:97-103
pubmed: 26164388
Hepatology. 2023 Feb 27;:
pubmed: 36825598
World J Gastroenterol. 2016 Nov 7;22(41):9172-9185
pubmed: 27895404
J Hepatol. 2021 Jul;75(1):232-234
pubmed: 33484772
Hepatology. 2023 Feb 1;77(2):640-658
pubmed: 35665949
Dig Liver Dis. 2019 Dec;51(12):1685-1691
pubmed: 31221548
Clin Chem Lab Med. 2020 Oct 23;59(4):775-782
pubmed: 33095752
Hepatology. 2020 Oct;72(4):1327-1340
pubmed: 32614088
J Infect Chemother. 2005 Oct;11(5):234-8
pubmed: 16258819
Gut. 2023 Aug;72(8):1581-1591
pubmed: 36788015
United European Gastroenterol J. 2021 May;9(4):421-422
pubmed: 33939291
J Hepatol. 2021 May;74(5):1265-1267
pubmed: 33640401
J Hepatol. 2013 May;58(5):911-21
pubmed: 23262249
Gut. 2015 Apr;64(4):531-7
pubmed: 25631669